1 Global Prescription Pharmaceuticals Market, By Therapeutic Segment (Cardiovascular Disorders, Inflammatory Conditions, Metabolic Disorders, Oncology, Respiratory Disorders, Others), By Formulations (Capsules, Inhalants, Parenterals, Tablets, Topicals), By Region (Asia, Europe, North America and Rest of the World (RoW) – Market Size and Forecast (2013–2020) Scalar Market Research. June 2016
41
Embed
Prescription pharmaceuticals market forecast to 2022 by scalar market research
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Global Prescription Pharmaceuticals Market, By TherapeuticSegment (Cardiovascular Disorders, Inflammatory Conditions,Metabolic Disorders, Oncology, Respiratory Disorders,Others), By Formulations (Capsules, Inhalants, Parenterals,Tablets, Topicals), By Region (Asia, Europe, North Americaand Rest of the World (RoW) – Market Size and Forecast(2013–2020)
1.1 Global Prescription Pharmaceuticals Market .......................................................................19
1.2 Global Prescription Pharmaceuticals Market Size (US$ Billion), By Therapeutic Segments(2015 vs. 2020)..................................................................................................................................20
1.3 Global Prescription Pharmaceuticals Market Size (US$ Billion), By Formulations (2015 vs.2020) 21
1.4 Global Prescription Pharmaceuticals Market Size (US$ Billion), By Regions (2015 vs. 2020)21
4.2.2 Global Prescription Pharmaceuticals for Cardiovascular Disorders Market Size &Forecast (US$ billion), By Regions (2015 vs. 2020) .......................................................................36
4.2.3 Global Prescription Pharmaceuticals for Cardiovascular Disorders Market Size &Forecast (US$ billion), By Regions (2013 – 2020) .........................................................................37
4.2.4 North America Prescription Pharmaceuticals for Cardiovascular Disorders Market Size& Forecast (US$ billion), By Country (2013 – 2020) .....................................................................37
4.2.5 Europe Prescription Pharmaceuticals for Cardiovascular Disorders Market Size &Forecast (US$ billion), By Country (2013 – 2020) .........................................................................38
4.2.6 Asia Prescription Pharmaceuticals for Cardiovascular Disorders Market Size (US$Billion) & Forecast (US$ billion), By Country (2013 – 2020) .........................................................38
4.2.7 Rest of the World (RoW) Prescription Pharmaceuticals for Cardiovascular DisordersMarket Size & Forecast (US$ billion), By Country (2013 – 2020)..................................................38
4.3.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Oncology(2013 – 2020) ................................................................................................................................39
4.3.2 Global Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$billion), By Regions (2015 vs. 2020) ..............................................................................................40
4.3.3 Global Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$billion), By Regions (2013 – 2020).................................................................................................40
4.3.4 North America Prescription Pharmaceuticals for Oncology Market Size & Forecast(US$ billion), By Country (2013 – 2020)........................................................................................41
SAMPLE
4
4.3.5 Europe Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$billion), By Country (2013 – 2020) ................................................................................................41
4.3.6 Asia Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion),By Country (2013 – 2020) .............................................................................................................42
4.3.7 Rest of the World (RoW) Prescription Pharmaceuticals for Oncology Market Size &Forecast (US$ billion), By Country (2013 – 2020) .........................................................................42
4.4.2 Global Prescription Pharmaceuticals Market Size & Forecast for InflammatoryConditions (US$ billion), By Regions (2015 vs. 2020) ...................................................................43
4.4.3 Global Prescription Pharmaceuticals Market Size & Forecast for InflammatoryConditions (US$ billion), By Regions (2013 – 2020)......................................................................44
4.4.4 North America Prescription Pharmaceuticals Market Size & Forecast for InflammatoryConditions (US$ billion), By Country (2013 – 2020)......................................................................44
4.4.5 Europe Prescription Pharmaceuticals Market Size & Forecast for InflammatoryConditions (US$ billion), By Country (2013 – 2020)......................................................................45
4.4.6 Asia Prescription Pharmaceuticals Market Size & Forecast for InflammatoryConditions (US$ billion), By Country (2013 – 2020)......................................................................45
4.4.7 Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast forInflammatory Conditions (US$ billion), By Country (2013 – 2020)...............................................45
4.5.2 Global Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases(US$ billion), By Regions (2015 vs. 2020)......................................................................................47
4.5.3 Global Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases(US$ billion), By Regions (2013 – 2020) ........................................................................................47
4.5.4 North America Prescription Pharmaceuticals Market Size & Forecast for InfectiousDiseases (US$ billion), By Country (2013 – 2020) .........................................................................48
4.5.5 Europe Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases(US$ billion), By Country (2013 – 2020)........................................................................................48
4.5.6 Asia Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases (US$billion), By Country (2013 – 2020) ................................................................................................48
4.5.7 Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast forInfectious Diseases (US$ billion), By Country (2013 – 2020) ........................................................49
4.6.2 Global Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders(US$ billion), By Regions (2015 vs. 2020)......................................................................................50
4.6.3 Global Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders(US$ billion), By Regions (2013 – 2020) ........................................................................................50
4.6.4 North America Prescription Pharmaceuticals Market Size & Forecast for MetabolicDisorders (US$ billion), By Country (2013 – 2020) .......................................................................51
4.6.5 Europe Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders(US$ billion), By Country (2013 – 2020)........................................................................................51
4.6.6 Asia Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders(US$ billion), By Country (2013 – 2020)........................................................................................51
4.6.7 Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast forMetabolic Disorders (US$ billion), By Country (2013 – 2020) ......................................................52
4.7.2 Global Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders(US$ billion), By Regions (2015 vs. 2020)......................................................................................53
4.7.3 Global Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders(US$ billion), By Regions (2013 – 2020) ........................................................................................53
4.7.4 North America Prescription Pharmaceuticals Market Size & Forecast for RespiratoryDisorders (US$ billion), By Country (2013 – 2020) .......................................................................54
4.7.5 Europe Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders(US$ billion), By Country (2013 – 2020)........................................................................................54
4.7.6 Asia Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders(US$ billion), By Country (2013 – 2020)........................................................................................55
4.7.7 Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast forRespiratory Disorders (US$ billion), By Country (2013 – 2020) ....................................................55
4.8 Other Therapeutic Segments ................................................................................................55
4.8.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By OtherTherapeutic Segments (2013 – 2020) ...........................................................................................56
4.8.2 Global Prescription Pharmaceuticals Market Size & Forecast for Other TherapeuticSegments (US$ billion), By Regions (2015 vs. 2020) .....................................................................56
4.8.3 Global Prescription Pharmaceuticals Market Size & Forecast for Other TherapeuticSegments (US$ billion), By Regions (2013 – 2020) .......................................................................57
SAMPLE
6
4.8.4 North America Prescription Pharmaceuticals Market Size & Forecast for OtherTherapeutic Segments (US$ billion), By Country (2013 – 2020)...................................................57
4.8.5 Europe Prescription Pharmaceuticals Market Size & Forecast for Other TherapeuticSegments (US$ billion), By Country (2013 – 2020) .......................................................................57
4.8.6 Asia Prescription Pharmaceuticals Market Size & Forecast for Other TherapeuticSegments (US$ billion), By Country (2013 – 2020) .......................................................................58
4.8.7 Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast forOther Therapeutic Segments (US$ billion), By Country (2013 – 2020) ........................................58
5 Prescription Pharmaceuticals Markets, by Formulations .............................................................59
6.1.1 Global Prescription Pharmaceuticals Market Size vs. CAGR% (2015 – 2020), By Regions.......................................................................................................................................69
6.1.2 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Regions(2013 – 2020) ................................................................................................................................69
6.2 North America.......................................................................................................................70
6.2.1 North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByCountry (2013 – 2020) ..................................................................................................................70
6.2.2 North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion),(2013 – 2020) ................................................................................................................................70
6.2.3 North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByTherapeutic Segments (2013 – 2020) ...........................................................................................71
6.2.4 North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByFormulations (2013 – 2020)..........................................................................................................72
8.4.2 Revenues of Top-3 Pharmaceutical Products: GlaxoSmithKline plc (U.K.) (Europe)(2013 to 2015)...............................................................................................................................86
8.5 Johnson & Johnson (U.S.)......................................................................................................87
8.5.1 Financial Overview: Johnson & Johnson (U.S.) (2013 to 2015) ....................................87
8.5.2 Revenues of Top-3 Pharmaceutical Products: Johnson & Johnson (U.S.) (2013 to 2015).......................................................................................................................................88
8.6 Merck & Co (U.S)...................................................................................................................88
8.6.1 Financial Overview: Merck & Co., Inc. (U.S.) (2013 to 2015)........................................88
SAMPLE
9
8.6.2 Revenues of Top-3 Pharmaceutical Products: Merck & Co., Inc. (U.S.) (2013 to 2015)89
8.7.1 Financial Overview: Novartis AG (Switzerland) (Europe) (2013 to 2015).....................90
8.7.2 Revenues of Top-3 Pharmaceutical Products: Novartis AG (Switzerland) (Europe)(2013 to 2015)...............................................................................................................................91
10.2 Contact Us................................................................................ Error! Bookmark not defined.
10.3 Disclaimer................................................................................. Error! Bookmark not defined.SAMPLE
10
Table 1. Global Prescription Pharmaceuticals Market ...................................................................19
Table 2. Global Prescription Pharmaceuticals Market Size (US$ Billion), By Therapeutic Segments(2015 vs. 2020)......................................................................................................................................20
Table 13. Global Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast(US$ billion), By Regions (2013 – 2020) ................................................................................................37
Table 14. North America Prescription Pharmaceuticals for Cardiovascular Disorders Market Size &Forecast (US$ billion), By Country (2013 – 2020) .................................................................................37
Table 15. Europe Prescription Pharmaceuticals for Cardiovascular Disorders Market Size &Forecast (US$ billion), By Country (2013 – 2020) .................................................................................38
Table 16. Asia Prescription Pharmaceuticals for Cardiovascular Disorders Market Size (US$ Billion)for Asia, By Country (2013 – 2020) .......................................................................................................38
Table 17. Rest of the World (RoW) Prescription Pharmaceuticals for Cardiovascular DisordersMarket Size & Forecast (US$ billion), By Country (2013 – 2020) .........................................................38
Table 18. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Oncology(2013 – 2020) ........................................................................................................................................39
Table 19. Global Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion),By Regions (2013 – 2020)......................................................................................................................40
Table 20. North America Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$billion), By Country (2013 – 2020) ........................................................................................................41
Table 21. Europe Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion),By Country (2013 – 2020) .....................................................................................................................41
SAMPLE
11
Table 22. Asia Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion), ByCountry (2013 – 2020) ..........................................................................................................................42
Table 23. Rest of the World (RoW), Prescription Pharmaceuticals for Oncology Market Size &Forecast (US$ billion),By Country (2013 – 2020) ..................................................................................42
Table 25. Global Prescription Pharmaceuticals Market Size & Forecast for Inflammatory Conditions(US$ billion), By Regions (2013 – 2020) ................................................................................................44
Table 26. North America Prescription Pharmaceuticals Market Size & Forecast for InflammatoryConditions (US$ billion), By Country (2013 – 2020)..............................................................................44
Table 27. Europe Prescription Pharmaceuticals Market Size & Forecast for InflammatoryConditions (US$ billion), By Country (2013 – 2020)..............................................................................45
Table 28. Asia Prescription Pharmaceuticals Market Size & Forecast for Inflammatory Conditions(US$ billion), By Country (2013 – 2020)................................................................................................45
Table 29. Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast forInflammatory Conditions (US$ billion), By Country (2013 – 2020).......................................................45
Table 30. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By InfectiousDiseases (2013 – 2020) .........................................................................................................................46
Table 31. Global Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases (US$billion), By Regions (2015 vs. 2020) ......................................................................................................47
Table 32. Global Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases (US$billion), By Regions (2013 – 2020).........................................................................................................47
Table 33. North America Prescription Pharmaceuticals Market Size & Forecast for InfectiousDiseases (US$ billion), By Country (2013 – 2020) .................................................................................48
Table 34. Europe Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases(US$ billion), By Country (2013 – 2020)................................................................................................48
Table 35. Asia Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases (US$billion), By Country (2013 – 2020) ........................................................................................................48
Table 36. Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast forInfectious Diseases (US$ billion), By Country (2013 – 2020) ................................................................49
Table 37. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By MetabolicDisorders (2013 – 2020)........................................................................................................................49
Table 38. Global Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders(US$ billion), By Regions (2013 – 2020) ................................................................................................50
Table 39. North America Prescription Pharmaceuticals Market Size & Forecast for MetabolicDisorders (US$ billion), By Country (2013 – 2020) ...............................................................................51
Table 40. Europe Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders(US$ billion), By Country (2013 – 2020)................................................................................................51
SAMPLE
12
Table 41. Asia Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders (US$billion), By Country (2013 – 2020) ........................................................................................................51
Table 42. Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast forMetabolic Disorders (US$ billion), By Country (2013 – 2020) ..............................................................52
Table 43. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By RespiratoryDisorders (2013 – 2020)........................................................................................................................52
Table 44. Global Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders(US$ billion), By Regions (2013 – 2020) ................................................................................................53
Table 45. North America Prescription Pharmaceuticals Market Size & Forecast for RespiratoryDisorders (US$ billion), By Country (2013 – 2020) ...............................................................................54
Table 46. Europe Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders(US$ billion), By Country (2013 – 2020)................................................................................................54
Table 47. Asia Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders (US$billion), By Country (2013 – 2020) ........................................................................................................55
Table 48. Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast forRespiratory Disorders (US$ billion), By Country (2013 – 2020)............................................................55
Table 49. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By OtherTherapeutic Segments (2013 – 2020) ...................................................................................................56
Table 50. Global Prescription Pharmaceuticals Market Size & Forecast for Other TherapeuticSegments (US$ billion), By Regions (2013 – 2020) ...............................................................................57
Table 51. North America Prescription Pharmaceuticals Market Size & Forecast for OtherTherapeutic Segments (US$ billion), By Country (2013 – 2020)...........................................................57
Table 52. Europe Prescription Pharmaceuticals Market Size & Forecast for Other TherapeuticSegments (US$ billion), By Country (2013 – 2020) ...............................................................................57
Table 53. Asia Prescription Pharmaceuticals Market Size & Forecast for Other TherapeuticSegments (US$ billion), By Country (2013 – 2020) ...............................................................................58
Table 54. Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast for OtherTherapeutic Segments (US$ billion), By Country (2013 – 2020)...........................................................58
Table 85. Financial Overview: Bayer AG (Germany) (Europe) (2013 to 2015) .................................83
Table 86. Revenues of Top-3 Pharmaceutical Products: Bayer AG (Germany) (Europe) (2013 to2015) ...........................................................................................................................................83
Table 87. Financial Overview: Gilead Sciences, Inc. (U.S.) (2013 to 2015) .......................................84
Table 88. Revenues of Top-3 Pharmaceutical Products: Gilead Sciences, Inc. (U.S.) (2013 to 2015) .............................................................................................................................................85
Figure 3. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By TherapeuticSegments (2015) ...................................................................................................................................34
Figure 4. Global Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast(US$ billion), By Regions (2015 vs. 2020)..............................................................................................36
Figure 5. Global Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion),By Regions (2015 vs. 2020) ...................................................................................................................40
Figure 6. Global Prescription Pharmaceuticals Market Size & Forecast for Inflammatory Conditions(US$ billion), By Regions (2015 vs. 2020)..............................................................................................43
Figure 7. Global Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders(US$ billion), By Regions (2015 vs. 2020)..............................................................................................50
Figure 8. Global Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders(US$ billion), By Regions (2015 vs. 2020)..............................................................................................53
Figure 9. Global Prescription Pharmaceuticals Market Size & Forecast for Other TherapeuticSegments (US$ billion), By Regions (2015 vs. 2020).............................................................................56
Figure 11. Global Capsules Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020) ....61
Figure 12. Global Tablets Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020).......62
Figure 13. Global Inhalants and Liquids Market Size & Forecast (US$ billion), By Regions (2015vs. 2020) .......................................................................................................................................64
Figure 14. Global Parenteral Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020) .66
Figure 15. Global Topicals Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020) ......67
Figure 16. Global Prescription Pharmaceuticals Market Size vs. CAGR% (2015 – 2020), By Regions.......................................................................................................................................69
1.2 Global Prescription Pharmaceuticals Market Size (US$ Billion), ByTherapeutic Segments (2015 vs. 2020)
Table 2. Global Prescription Pharmaceuticals Market Size (US$ Billion), ByTherapeutic Segments (2015 vs. 2020)
Table 3.
Source: Scalar Market Research Analysis
The therapeutic segments of the prescription pharmaceuticals market included in this
report are cardiovascular disorders, oncology, inflammatory conditions, infectious
diseases, metabolic disorders, respiratory disorders, and other therapeutic
segments. Cardiovascular disorders were the largest therapeutic segment in 2015.
This segment was estimated to be US$ XX billion in 2015. On the other hand,
infectious diseases are expected to be the fastest-growing therapeutic segment in
the forecast period. This market segment is expected to grow at a CAGR of XX%
between 2015 and 2020.
129.
05
117.
53
110.
28
95.3
8
83.4
4
36.8
7
154.
34
157.
91
152.
20
138.
36
125.
62
107.
55
44.0
6
193.
03
4.12
5.314.64
5.66 5.21
3.63
4.58
CardiovascularDisorders
Oncology InflammatoryConditions
InfectiousDiseases
MetabolicDisorders
RespiratoryDisorders
Other TherapeuticSegments
CAGR
% (2
015
–20
20)
Mar
ket S
ize (U
SD B
illio
n)
2015 2020 CAGR% (2015 – 2020)
SAMPLE
21
1.3 Global Prescription Pharmaceuticals Market Size (US$ Billion), ByFormulations (2015 vs. 2020)
Table 4. Global Prescription Pharmaceuticals Market Size (US$ Billion), ByFormulations (2015 vs. 2020)
Source: Scalar Market Research Analysis
The formulation segments of the prescription pharmaceuticals market included in this
report are capsules, tablets, inhalants and liquids, parenteral, and topicals. Capsules
were the largest formulation segment in 2015. This segment was estimated to be
US$ XX billion in 2015. It is also expected to be the fastest-growing formulation
segment in the forecast period. This market segment is expected to grow at a CAGR
of XX% between 2015 and 2020.
1.4 Global Prescription Pharmaceuticals Market Size (US$ Billion), ByRegions (2015 vs. 2020)
Table 5. Global Prescription Pharmaceuticals Market Size (US$ Billion), ByRegions (2015 vs. 2020)
269.
45
247.
42
103.
69
71.3
4
34.9
9
356.
16
304.
42
127.
34
89.7
6
41.0
6
5.74
4.23 4.194.70
3.26
Capsules Tablets Inhalants andLiquids
Parenterals Topicals
CAGR
% (2
015
–20
20)
Mar
ket S
ize (U
SD B
illio
n)
2015 2020 CAGR% (2015 – 2020)
295.
77
183.
98
158.
10
89.0
4
364.
41
219.
20
219.
73
115.
40
4.263.57
6.80
5.32
North America Europe Asia RoW
CAGR
% (2
015
–20
20)
Mar
ket S
ize (U
SD B
illio
n)
2015 2020 CAGR% (2015 – 2020)
SAMPLE
22
Source: Scalar Market Research Analysis
The regional segments of the prescription pharmaceuticals market included in this
report are North America, Europe, Asia, and Rest of the World (RoW). North
America was the largest regional segment in 2015. This segment was estimated to
be US$ XX billion in 2015. On the other hand, Asia is expected to be the fastest-
growing regional segment in the forecast period. This market segment is expected to
grow at a CAGR of XX% between 2015 and 2020.
SAMPLE
23
2 Market Overview
2.1 Drivers
2.1.1 Increase in the Ageing Population and Lengthening Life ExpectanciesAccording to the World Health Organization (WHO), in 2010 around 8% of the global
population was aged 65 years and above. In 2015, the elderly population comprised
around 12% of the global population. It has been estimated that by 2050, about 2.1
billion people will be aged above 60 years. The evolution of the population structure
will lead to increased pressure on long-term publicly-funded health, support
programmes for older people. There will be a paradigm shift from acute to chronic
illnesses thereby leading to an increased use of prescription pharmaceuticals.
The rising life expectancy within the older population segment is leading to an
increase in the number and proportion of people at very old ages. People aged 85 or
older constitute around 12% and 6% of world’s 65 and above population in
developed and developing economies respectively. According to Economist
Intelligence Unit (EIU), life expectancy is expected to increase from an estimated
72.7 years in 2013 to 73.7 years by 2018. This will result in a rise in global health
care and life sciences spending.
2.1.2 Rising Affluence in Emerging MarketsGrowing consumer wealth and income levels, increasing government and patient
awareness, and a trend towards healthier lifestyles are anticipated to boost health
care spending to around 8.1% between 2014 and-2018 in Asia. Factors such as
government focus on broader welfare policies and economic expansion will drive the
market for prescription pharmaceuticals. BRICS (Brazil, Russia, India, China, and
South Africa) are among the fastest-growing global economies. According to the
World Economic Forum report, by 2022 around one-third of all global health
expenditure will occur in emerging economies. Increased healthcare spending and
improved access to healthcare in emerging economies will drive the global
prescription pharmaceuticals market.
2.1.3 Widespread Prevalence of Chronic DiseasesChronic diseases namely, heart disease, stroke, cancer, type 2 diabetes, obesity,
and arthritis pose a serious threat to the health of world population. The mortality
SAMPLE
30
formation of the ASEAN Economic Community (AEC) to define the regulatory
landscape for this region.
Thus, across the globe, a strong trend is being observed towards consolidation of
legislature systems into a global drug safety system with balanced business
processes.
3.3 Macroeconomic Indicators
3.3.1 Healthcare Spending (US$ Billion), by Regions (2005 to 2014)Table 6. Healthcare Spending (US$ Billion), by Regions (2005 to 2014)
Source: World Bank and Scalar Market Research Analysis
3.4 Ecosystem Analysis
3.4.1 Market Size of Top-25 Prescription Pharmaceuticals (2013 to 2015)Table 9. Market Size of Top-25 Prescription Pharmaceuticals (2013 to 2015)No. Product Company Indication 2015
(US$million)
2014(US$million)
2013(US$million)
AnnualGrowth(2014 to2015)
AnnualGrowth(2013 to2014)
U.S. PatentExpiry
1 Humira AbbVie Inc. (U.S.) Rheumatoidarthritis andotherinflammatoryconditions
14,021 12,543 10,659 11.78% 17.68% December2016
2 Harvoni Gilead Sciences, Inc.(U.S.)
Hepatitis C 13,864 2,127 N.A. 551.81%
N.A. 2030
3 Enbrel Amgen Inc. (U.S.),Pfizer Inc. (U.S.),Takeda PharmaceuticalCompany Ltd. (Japan)
4.2.7 Rest of the World (RoW) Prescription Pharmaceuticals forCardiovascular Disorders Market Size & Forecast (US$ billion), ByCountry (2013 – 2020)
Table 17. Rest of the World (RoW) Prescription Pharmaceuticals for CardiovascularDisorders Market Size & Forecast (US$ billion), By Country (2013 – 2020)
6.1 IntroductionThe regional segments of the prescription pharmaceuticals market included in this report are NorthAmerica, Europe, Asia, and Rest of the World (RoW). North America was the largest regionalsegment in 2015, while Asia is expected to be the fastest-growing regional segment in the forecastperiod.
6.1.1 Global Prescription Pharmaceuticals Market Size vs. CAGR% (2015 –2020), By Regions
Figure 16. Global Prescription Pharmaceuticals Market Size vs. CAGR% (2015 – 2020),By Regions
Source: Scalar Market Research Analysis
North America was the largest regional segments of the prescription
pharmaceuticals market in 2015. The market had a XX% share of the global market
in 2015.
6.1.2 Global Prescription Pharmaceuticals Market Size & Forecast (US$billion), By Regions (2013 – 2020)
Table 66. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion),By Regions (2013 – 2020)
Capsules were the largest formulation segment of the prescription pharmaceuticals
market in North America in 2015. This market segment is expected to grow at a
CAGR of XX% from US$ XX billion in 2015 to US$ 133.71 billion in 2020.
SAMPLE
80
7 Competitive Landscape
7.1 Market Share AnalysisThe market share analysis studies the market share of the leading players operating in theprescription pharmaceuticals market. This market share analysis exclusively focused on prescriptionpharmaceuticals products and is estimated based on considering the global pharmaceutical productsmarket revenue for the year 2015. The value percentage for each company is based on the analysisof company’s investor presentations, annual reports, press releases, product offering particular toprescription pharmaceuticals segment and opinion of primary respondents. The below market sharediagram represents the revenue regarding value percentage for 2015 for each leading playersoperating in this market.
Figure 17. Market Share Analysis
Source: Scalar Market Research Analysis
7.2 Market Positioning of Key PlayersThe figure below represents the top-10 companies based on the criteria's: annual revenue,
combined total revenue of top-3 drug products, annual growth, and R&D investment.
Figure 18. Market Positioning of Key Players
4.1%5.2%5.0%
6.0%2.0%4.8%
3.8%
4.7%3.2%
3.0%
58.2%
Johnson & Johnson
Roche
Pfizer
Novartis AG
Bayer AG
Merck & Co., Inc.
GlaxoSmithKline Plc
Sanofi
Gilead Sciences
Astrazeneca
Others
SAMPLE
96
9 SCALAR 360 DEGREE MARKET REVIEWThe usage of prescription drugs over the years is set to increase across the globe. Nearly half of thisvolume growth is expected to occur in emerging markets, with India, China, Brazil and Indonesiadriving the spike in demand. In the developed markets, the volume of medicine use will remainstable. However, there will be an inclination towards the use of branded products as the use ofbiologics, or specialty medicines become more prevalent. The generic drugs, over the counter (OTC)products and imitative branded products, will fare better in the pharmerging markets and accountfor around 88% of total medicine use by 2020. The innovative specialty medicines have low adoptionrates in these countries.
Over the forecast period, a large number of innovative medicines is set to emerge from R&Dpipelines with products being focused on cancer, hepatitis C, autoimmune disorders, heart diseaseand some rare diseases. Owing to the presence of unparalleled treatment options, availability ofcheap drugs and increased use of evidence for decision making, stakeholders across the globe areset to obtain a higher return for their medicine investment than before.
The rapid development of technology will lead to changes in the treatment protocols, increase thepatient accountability and engagement, and accelerate the rate of adoption of behavioral changesthereby improving patient adherence to treatments. Patients suffering from multiple chronicdisorders can use wearables, mobile apps and other technologies to interact with providers andmanage their health.
The healthcare spending levels in developed markets will increase owing to branded drugs whereasgenerics will drive the spending levels in pharmerging markets. However, owing to the patentexpiries, around $150 billion would be saved on branded products, while over $30-40 billion wouldbe saved on biologics as biosimilars become widely adopted. Also, a large number of drugs focusedon chronic, rare or genetic diseases are expected to be launched thereby rendering significantclinical value.
Thus, the market is undergoing an evolution with traditional bigwigs, such as U.S and Europe,flipping over, and emerging markets giving rise to new potential markets. The healthcare investorsalso require rethinking a strategy by keeping an eagle eye on the emerging markets. They need tomake sure that they are not left behind owing to their low understanding of the true engines forgrowth.
10 Appendix
10.1 AcronymsTable 103. Acronyms
OTC Over the Counter
U.S. United States
GIP Global Innovative Pharma
GEP Global Established Pharma
VOC Vaccines, Oncology and Consumer Healthcare
R&D Research and Development
SAMPLE
97
U.K. United Kingdom
HCV Hepatitis C virus
HIV Human Immunodeficiency Virus
RoW Rest of the World
CAGR Compound annual growth rate
ACA Patient Protection and Affordable Care Act
COPD Chronic obstructive pulmonary disease
WHO World Health Organization
AARDAAmerican Autoimmune Related Diseases
Association
IMID Immune-mediated inflammatory diseases
SLE Systemic Lupus Erythematosus
RA Rheumatoid Arthritis
CHD Chronic Heart Disease
ASEAN Association of South-East Asian Nations
AEC ASEAN Economic Community
EMA European Medicines Agency
IDMP Identification of Medicinal Products
GVP Good Pharmacovigilance Practices
FDA Food and Drug Administration
GUDID Global Unique Device Identification DatabaseSAMPLE